Skip to main content
. 2022 Oct 20;9:1023583. doi: 10.3389/fmed.2022.1023583

Figure 2.

Figure 2

(A,B) Adjusted means of metabolic phenotypes of fatty liver disease with visceral adipose tissue and visceral adipose tissue/subcutaneous adipose tissue ratio. 95% CI, 95% confidence interval; FLD, fatty liver disease; MAFLD, metabolic dysfunction–associated fatty liver disease; MD, metabolic dysfunction; MHO, metabolically healthy obesity; MUHO, metabolically unhealthy obesity; T2D, type 2 diabetes; VAT, visceral adipose tissue; VAT/SCAT ratio, visceral adipose tissue/subcutaneous adipose tissue ratio.